Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 17/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 15/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19397136 | 0.92 | PRMT5 (0.36) | PRMT5WDR77ADK | |
| SCHEMBL19379653 | 0.92 | FAP (0.37) | PRMT5WDR77ADK | |
| SCHEMBL19397140 | 0.91 | PRMT5 (0.36) | PRMT5WDR77ADK | |
| SCHEMBL19397146 | 0.82 | P2RY2 (0.41) | PRMT5WDR77ADK | |
| SCHEMBL19401320 | 0.81 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL19379667 | 0.79 | PRMT5 (0.43) | PRMT5WDR77ADK | |
| SCHEMBL19379660 | 0.79 | PRMT5 (0.43) | PRMT5WDR77ADK | |
| SCHEMBL19401321 | 0.75 | FAP (0.38) | PRMT5WDR77ADK | |
| SCHEMBL21078516 | 0.73 | P2RY1 (0.42) | PRMT5WDR77ADK | |
| SCHEMBL31228569 | 0.73 | P2RY1 (0.42) | PRMT5WDR77ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433257-B1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-10428105-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2019-10-01 | — | — | US | disclosed |
| US-9988416-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-9988416-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) | 2017-09-28 | — | — | US | disclosed |
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | RNASEH1, ENTPD5, SARNP | PRMT5 1834/4885WDR77 1571/4885ADK 578/4885 |
| US-10428105-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | RNASEH1, ENTPD5, SARNP | PRMT5 1834/4885WDR77 1571/4885ADK 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.